Context: A recent study published in The New England Journal of Medicine reported that the antiviral drug Ensitrelvir significantly reduced symptomatic COVID-19 infections among exposed household contacts.
About Antiviral Drug Ensitrelvir:
What It Is?
- Ensitrelvir is an oral antiviral drug that inhibits the SARS-CoV-2 main protease (3C-like protease/Mpro), an enzyme essential for viral replication.
- By blocking this protease, the drug prevents the coronavirus from processing viral proteins required for multiplication inside human cells.
Aim:
- To treat mild-to-moderate COVID-19 infections and reduce viral transmission after exposure.
- To provide a safer and longer-lasting oral antiviral option without requiring booster drugs like ritonavir.
Key Features:
- Protease Inhibitor Mechanism: Targets the SARS-CoV-2 main protease (Mpro), preventing viral replication.
- Oral Antiviral Drug: Can be administered orally, making it suitable for outpatient and household use.
- Broad Variant Activity: Showed effectiveness against multiple SARS-CoV-2 variants, including Omicron.
- Better Safety Profile: Remains longer in the bloodstream without requiring ritonavir and avoids the bitter aftertaste associated with some COVID antivirals.
- SCORPIO-PEP Trial Findings: Reduced symptomatic COVID-19 incidence from 9% to 2.9% among exposed household contacts.
Significance:
- Represents a major advancement in post-exposure prophylaxis for COVID-19, especially for high-risk household contacts.
- Provides a potential starting point for future antiviral treatments against related betacoronaviruses like SARS and MERS.
Relevance in UPSC Exam Syllabus
- GS Paper 2
- Public health and healthcare systems
- Government responses to pandemics and infectious diseases
- GS Paper 3
- Biotechnology and medical innovations
- Science and technology developments
- Pharmaceutical research and antiviral drugs
